Ignite Creation Date:
2025-12-25 @ 5:04 AM
Ignite Modification Date:
2025-12-26 @ 4:06 AM
Study NCT ID:
NCT03966118
Status:
UNKNOWN
Last Update Posted:
2019-06-03
First Post:
2019-02-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma
Sponsor:
P. C. Thuss-Patience
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-04-01
Start Date Type:
ACTUAL
Primary Completion Date:
2022-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2023-09
Completion Date Type:
ESTIMATED
First Submit Date:
2019-02-12
First Submit QC Date:
None
Study First Post Date:
2019-05-29
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-05-30
Last Update Post Date:
2019-06-03
Last Update Post Date Type:
ACTUAL